TRAVOPROST

Search structure
Trade Names:
Synonyms:
Status: Approved (2001)
Entry Type: Small molecule
Molecule Category: UNKNOWN Prodrug
ATC: S01EE04
UNII: WJ68R08KX9

Structure
InChI Key MKPLKVHSHYCHOC-AHTXBMBWSA-N
Smile CC(C)OC(=O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/[C@@H](O)COc1cccc(C(F)(F)F)c1
InChI
InChI=1S/C26H35F3O6/c1-17(2)35-25(33)11-6-4-3-5-10-21-22(24(32)15-23(21)31)13-12-19(30)16-34-20-9-7-8-18(14-20)26(27,28)29/h3,5,7-9,12-14,17,19,21-24,30-32H,4,6,10-11,15-16H2,1-2H3/b5-3-,13-12+/t19-,21-,22-,23+,24-/m1/s1

Physicochemical Descriptors

Property Name Value
Molecular Formula C26H35F3O6
Molecular Weight 500.55
AlogP 4.43
Hydrogen Bond Acceptor 6.0
Hydrogen Bond Donor 3.0
Number of Rotational Bond 12.0
Polar Surface Area 96.22
Molecular species NEUTRAL
Aromatic Rings 1.0
Heavy Atoms 35.0

Pharmacology

Action Mechanism of Action Reference
AGONIST Prostanoid FP receptor agonist DailyMed
Targets EC50(nM) IC50(nM) Kd(nM) Ki(nM) Inhibition(%)
Ion channel Other ion channel Pore-forming toxins (proteins and peptides)
- - - - 0
Transporter Primary active transporter ATP-binding cassette ABCB subfamily
- 43900 - - -
Transporter Primary active transporter ATP-binding cassette ABCC subfamily
- 74000 - - -

Indications

Mesh Heading Maximum Phase Mesh ID Reference
Glaucoma 4 D005901 ClinicalTrials
Exfoliation Syndrome 3 D017889 ClinicalTrials

Related Entries

Scaffolds

Side Effects from Label

Side effects Relative Frequency (%) Labels
Vascular disorders Hyperaemia 37.3
Vascular disorders Hyperaemia 33.8
Eye disorders Iris hyperpigmentation 29.5
Vascular disorders Hyperaemia 24.0
Vascular disorders Hyperaemia 8.3
Skin and subcutaneous tissue disorders Pruritus 5.6
Skin and subcutaneous tissue disorders Pruritus 5.1
General disorders and administration site conditions Discomfort 4.8
General disorders and administration site conditions Discomfort 4.0
General disorders and administration site conditions Pain 3.5
General disorders and administration site conditions Discomfort 3.4
Eye disorders Dry eye 3.4
General disorders and administration site conditions Pain 3.4
Eye disorders Photophobia 2.8
General disorders and administration site conditions Discomfort
Eye disorders Dry eye
Eye disorders Lacrimation increased 2.1
General disorders and administration site conditions Sensation of foreign body 2.1
General disorders and administration site conditions Discomfort 2.0
General disorders and administration site conditions Sensation of foreign body 2.0
Eye disorders Vision blurred 2.0
Eye disorders Dry eye 1.8
Eye disorders Keratitis 1.5
Eye disorders Lacrimation increased 1.5
General disorders and administration site conditions Pain 1.5
Nervous system disorders Headache 1.4
Eye disorders Photophobia 1.4
Skin and subcutaneous tissue disorders Pruritus
Investigations Vital dye staining cornea present
Eye disorders Keratitis 1.1
Skin and subcutaneous tissue disorders Pruritus 1.1
Eye disorders Vision blurred 0.8
Eye disorders Dry eye 0.7
Eye disorders Iritis 0.7
Eye disorders Keratitis 0.7
Eye disorders Lacrimation increased 0.7
Skin and subcutaneous tissue disorders Pruritus 0.7
General disorders and administration site conditions Sensation of foreign body 0.7
Eye disorders Vision blurred 0.7
Eye disorders Dry eye 0.5
Eye disorders Photophobia 0.5
General disorders and administration site conditions Sensation of foreign body 0.5
Eye disorders Photophobia 0.4
Nervous system disorders Headache 0.3
Eye disorders Iritis 0.3
General disorders and administration site conditions Pain 0.3
Eye disorders Iritis 0.1
Investigations Vital dye staining cornea present 0.1

Adverse Reactions

SOC By Demographic Distribution
System Organ Classification (SOC)
Relative Frequency (%)
Eye disorders
32.56
Nervous system disorders
12.15
General disorders and administration site conditions
10.45
Injury, poisoning and procedural complications
5.94
Investigations
5.2
Skin and subcutaneous tissue disorders
4.03
Respiratory, thoracic and mediastinal disorders
3.92
Psychiatric disorders
3.73
Product issues
3.11
Vascular disorders
2.96
Gastrointestinal disorders
2.6
Musculoskeletal and connective tissue disorders
2.33
Cardiac disorders
2.25
Immune system disorders
2.08

Cross References

Resources Reference
CAS NUMBER 157283-68-6
ChEBI 746859
ChEMBL CHEMBL1200799
DrugBank DB00287
DrugCentral 2716
EPA CompTox DTXSID80896948
FDA SRS WJ68R08KX9
Human Metabolome Database HMDB0014432
Guide to Pharmacology 7102
PharmGKB PA164781371
PubChem 5282226
SureChEMBL SCHEMBL93818
ZINC ZINC000004474682
CONTENTS